title: Effect of Helicobacter pylori eradication on reflux esophagitis therapy: a multi-center randomized control study.
abstract: BACKGROUND
  Helicobacter pylori (H. pylori) frequently colonizes the stomach. Gastroesophageal reflux disease (GERD) is a common and costly disease. But the relationship of H. pylori and GERD is still unclear. This study aimed to explore the effect of H. pylori and its eradication on reflux esophagitis therapy.
  
  
  METHODS
  Patients diagnosed with reflux esophagitis by endoscopy were enrolled; based on rapid urease test and Warth-Starry stain, they were divided into H. pylori positive and negative groups. H. pylori positive patients were randomly given H. pylori eradication treatment for 10 days, then esomeprazole 20 mg bid for 46 days. The other patients received esomeprazole 20 mg bid therapy for 8 weeks. After treatment, three patient groups were obtained: H. pylori positive eradicated, H. pylori positive uneradicated, and H. pylori negative. Before and after therapy, reflux symptoms were scored and compared. Healing rates were compared among groups. The χ2 test and t-test were used, respectively, for enumeration and measurement data.
  
  
  RESULTS
  There were 176 H. pylori positive (with 92 eradication cases) and 180 negative cases. Healing rates in the H. pylori positive eradicated and H. pylori positive uneradicated groups reached 80.4% and 79.8% (P = 0.911), with reflux symptom scores of 0.22 and 0.14 (P = 0.588). Healing rates of esophagitis in the H. pylori positive uneradicated and H. pylori negative groups were, respectively, 79.8% and 82.2% (P = 0.848); reflux symptom scores were 0.14 and 0.21 (P = 0.546).
  
  
  CONCLUSIONS
  Based on esomeprazole therapy, H. pylori infection and eradication have no significant effect on reflux esophagitis therapy.
authors.forename: Yan
authors.initials: Y
authors.lastname: Xue
authors.affiliation: Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China.
authors.forename: Li-Ya
authors.initials: LY
authors.lastname: Zhou
authors.forename: San-Ren
authors.initials: SR
authors.lastname: Lin
authors.forename: Xiao-Hua
authors.initials: XH
authors.lastname: Hou
authors.forename: Zhao-Shen
authors.initials: ZS
authors.lastname: Li
authors.forename: Min-Hu
authors.initials: MH
authors.lastname: Chen
authors.forename: Xiu-E
authors.initials: XE
authors.lastname: Yan
authors.forename: Ling-Mei
authors.initials: LM
authors.lastname: Meng
authors.forename: Jing
authors.initials: J
authors.lastname: Zhang
authors.forename: Jing-Jing
authors.initials: JJ
authors.lastname: Lu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use; D064098:Esomeprazole / Q000627:therapeutic use; D004942:Esophagitis, Peptic / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology*; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology*; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects / Q000472:pathogenicity*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014011:Tinidazole / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D014011:Tinidazole; D000658:Amoxicillin; D064098:Esomeprazole